NASDAQ:HUGE FSD Pharma (HUGE) Stock Price, News & Analysis → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Free HUGE Stock Alerts $0.35 -0.03 (-8.49%) (As of 03:50 PM ET) Add Compare Share Share Today's Range$0.33▼$0.3850-Day Range$0.34▼$0.8652-Week Range$0.31▼$1.68Volume423,448 shsAverage Volume202,821 shsMarket Capitalization$13.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get FSD Pharma alerts: Email Address FSD Pharma MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.22) to ($0.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.95 out of 5 starsMedical Sector2466th out of 2,771 stocksPharmaceutical Preparations Industry1178th out of 1,288 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for FSD Pharma.Read more about FSD Pharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.00% of the float of FSD Pharma has been sold short.Short Interest Ratio / Days to CoverFSD Pharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FSD Pharma has recently decreased by 10.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFSD Pharma does not currently pay a dividend.Dividend GrowthFSD Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HUGE. Previous Next 3.8 News and Social Media Coverage News SentimentFSD Pharma has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for FSD Pharma this week, compared to 1 article on an average week.Search Interest5 people have searched for HUGE on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows10 people have added FSD Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, FSD Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.53% of the stock of FSD Pharma is held by insiders.Percentage Held by InstitutionsOnly 1.24% of the stock of FSD Pharma is held by institutions.Read more about FSD Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for FSD Pharma are expected to grow in the coming year, from ($0.22) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FSD Pharma is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FSD Pharma is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFSD Pharma has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about FSD Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monetary GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About FSD Pharma Stock (NASDAQ:HUGE)FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.Read More HUGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HUGE Stock News HeadlinesMay 9, 2024 | americanbankingnews.comEquities Analysts Set Expectations for FSD Pharma Inc.'s Q1 2024 Earnings (NASDAQ:HUGE)May 9, 2024 | americanbankingnews.comSingular Research Reiterates "Buy-Venture" Rating for FSD Pharma (NASDAQ:HUGE)April 29, 2024 | msn.comNeural Networks And AI's Rapid Progression Ignite A Multi-Trillion-Dollar Economic ShiftApril 29, 2024 | seekingalpha.comWall Street Breakfast: Self-Driving PushApril 29, 2024 | thestreet.comTesla shares soar as Elon Musk returns from China with FSD 'Game Changer'April 29, 2024 | msn.comApple, Amazon, Fed Rates Could Have a Devastating Effect on Stocks, Here’s Why. And 5 Other Things to Know Before Markets Open.April 23, 2024 | finance.yahoo.comUS to provide 'significant' new security assistance for Ukraine, Biden tells ZelenskiyApril 23, 2024 | news.yahoo.comI’m a doctor in Haiti. Crisis may be death sentence for many with health problems | OpinionApril 22, 2024 | finanznachrichten.deFSD Pharma Inc.: FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzdApril 18, 2024 | msn.comSaudi Arabia Earns Top Marks in Global AI Index for National StrategyApril 18, 2024 | seekingalpha.comTesla Stock: Plunging Toward My Price TargetApril 17, 2024 | uk.investing.comFSD Pharma boosts loan to Celly Nutrition for new beverageApril 8, 2024 | msn.comTesla markets its FSD V12 with impressive real-world resultsMarch 29, 2024 | msn.comWalgreens’ frail quarter goes beyond the discretionary spending dips afflicting its competitors. It’s ‘just not very good at retailing,’ analyst saysMarch 28, 2024 | msn.comTesla stock slips as analysts issue a fresh round of warnings on Q1 deliveriesMarch 16, 2024 | benzinga.comPsychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News ReviewMarch 14, 2024 | msn.comMadrigal and liver drug developers fall ahead of FDA decision on NASH therapyMarch 11, 2024 | finance.yahoo.comFSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)March 7, 2024 | investing.comFSD Pharma reports positive Phase-1 MS drug trial resultsMarch 5, 2024 | finance.yahoo.comFSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 ForumFebruary 17, 2024 | finance.yahoo.comHUGE Mar 2024 1.000 callFebruary 16, 2024 | finanznachrichten.deFSD Pharma Inc.: FSD Pharma Announces US ATM OfferingFebruary 16, 2024 | finance.yahoo.comFSD Pharma Announces US ATM OfferingFebruary 6, 2024 | msn.comBig Pharma Targets Smaller Companies With Megadeals Out of FavorFebruary 6, 2024 | finanznachrichten.deFSD Pharma Inc.: Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 MillionSee More Headlines Receive HUGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/14/2024Next Earnings (Estimated)5/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HUGE CUSIPN/A CIK1771885 Webfsdpharma.com Phone(416) 854-8884FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-112.38% Return on Assets-82.46% Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio2.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book1.15Miscellaneous Outstanding Shares40,120,000Free Float36,695,000Market Cap$15.19 million OptionableOptionable Beta0.71 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Zeeshan Saeed (Age 54)Founder, CEO, President & Executive Co-Chairman Comp: $222.62kMr. Anthony John Durkacz (Age 48)Founder & Executive Co-Chairman Comp: $222.62kMr. Nathan Coyle CPA (Age 43)Chief Financial Officer Comp: $178.21kMr. Donal Carroll CPA (Age 47)Chief Operating Officer Comp: $225.62kDr. Lakshmi P. Kotra BPHARM (Age 53)Ph.D., CEO of Lucid & Director Comp: $144.72kMs. Maryann AdessoCorporate SecretaryRandell MackPresident of FSD BioSciencesDr. Andrzej Chruscinski M.D.Ph.D., Vice President of Clinical & Scientific Affairs of LucidMr. Kevin CassidyVice President of Quality-LucidMore ExecutivesKey CompetitorsEdesa BiotechNASDAQ:EDSAPieris PharmaceuticalsNASDAQ:PIRSAvalo TherapeuticsNASDAQ:AVTXRedHill BiopharmaNASDAQ:RDHLMonopar TherapeuticsNASDAQ:MNPRView All CompetitorsInstitutional OwnershipAdvisorShares Investments LLCBought 34,679 shares on 2/14/2024Ownership: 0.687%View All Institutional Transactions HUGE Stock Analysis - Frequently Asked Questions How have HUGE shares performed in 2024? FSD Pharma's stock was trading at $0.9198 on January 1st, 2024. Since then, HUGE stock has decreased by 62.2% and is now trading at $0.3480. View the best growth stocks for 2024 here. When is FSD Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024. View our HUGE earnings forecast. How were FSD Pharma's earnings last quarter? FSD Pharma Inc. (NASDAQ:HUGE) released its quarterly earnings data on Thursday, March, 28th. The company reported ($0.04) EPS for the quarter. What other stocks do shareholders of FSD Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other FSD Pharma investors own include Aurora Cannabis (ACB), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Assertio (ASRT), Bionano Genomics (BNGO), Ideanomics (IDEX), Stealth BioTherapeutics (MITO), Millendo Therapeutics (MLND), 9 Meters Biopharma (NMTR) and Selecta Biosciences (SELB). How do I buy shares of FSD Pharma? Shares of HUGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HUGE) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDid Intel Just Dethrone Nvidia?Chaikin AnalyticsDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmerica’s worst nightmare?Porter & CompanyHow to Make 100X on the AI BoomInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FSD Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
